Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia
Matteo Giovanni Della Porta, Cristina Picone, Annamaria Tenore, Norio Yokose, Luca Malcovati, M. Cazzola, K. Ogata
Abstract
Open-access reader
Matteo Giovanni Della Porta, Cristina Picone, Annamaria Tenore, Norio Yokose, Luca Malcovati, M. Cazzola, K. Ogata
Abstract
Open-access reader
The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which represents the basis of the WHO classification of these disorders.[1][1] The WHO proposal has raised some concern regarding minimal morphological criteria for formulating the diagnosis of MDS, since morphological
OpenAlex reports 23 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which represents the basis of the WHO classification of these disorders.[1][1] The WHO proposal has raised some concern regarding minimal morphological criteria for formulating the diagnosis of MDS, since morphological
Key concepts: Dysplasia, Myelodysplastic syndromes, Pathological, Bone marrow, Pathology, Immunophenotyping, Medicine, Clinical significance